Broadening the Understanding of Medical Students' Discussion of Radiology Online: A Social Listening Study of Reddit.

Reddit.com contains one of the largest online social forums for medical students, the 'r/medicalschool' subreddit. The platform provides an opportunity to share news and discuss a variety of topics including specialty choice and residency applications. In this study we analyze posts on the subreddit r/medicalschool with the aim of understanding how medical students perceive radiology as a career and what factors influence their decision to pursue radiology. Reddit posts to were collected from the r/medicalschool subreddit (2009-2022) and a randomized sample of the corpus was labeled to yield 2000 posts that discussed radiology as career and 1542 posts not discussing radiology. Sentiment analysis of the labeled corpus was conducted using the SiEBRT RoBERTa transformer sentiment pipeline, a machine trained English language text analyzer. Student's t-test was used to compare sentiment of posts discussing radiology to nonradiology posts by career keywords. Posts discussing radiology as a career had an overall positive sentiment but were lower than nonradiology posts' sentiment (p<.001). Key words associated with a positive sentiment score were "procedure", "lifestyle", "income", "fit", "personality", "anatomy", "tech", "physics", "research," and "match." Negative sentiment score included key words "AI", "burnout", "culture", "job market", "midlevel", "sue", "teleradiology." "Procedures" had the most positive sentiment score, while "AI" had the most negative score. Our study highlights aspects of radiology as a career that are discussed positively and negatively on Reddit. These posts are read by medical students around the world and may influence their choice of specialty.

Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis.

Background: Individuals aged ≥75 years are the fastest-growing population starting dialysis for end-stage kidney disease (ESKD) due to living longer with coronary artery disease. ESKD alone can increase bleeding risk, but P2Y12 inhibitor (P2Y12-I) antiplatelet medications prescribed for cardiovascular treatment can exacerbate this risk in patients with ESKD. The age-specific rates of bleeding complications in dialysis patients with ESKD on P2Y12-I remain unclear, as does how age modifies the bleeding risk from P2Y12-I use in these patients. Methods: In a retrospective cohort study, we collected data on 40,972 patients receiving maintenance hemo- or peritoneal dialysis who were newly prescribed P2Y12-I therapy between 2011 and 2015 from the USRDS registry. We analyzed the effect of age on the time to first bleed and the interactions between age and P2Y12-I type on modifying the effects of a bleed. Results: Twenty percent of the cohort were aged ≥75 years. There were 3096 (8%) gastrointestinal (GI) and 1298 (3%) intracranial (IC) bleeding events during a median follow-up of 1 year. Annual incidence rates for IC bleeds were 2% in those aged <55 years and 3% in those aged ≥75 years. Rates for GI bleeds were 4% in those aged <55 years and 9% in those aged ≥75 years. On clopidogrel, prasugrel, and ticagrelor, for every decade increase in age of the cohort members, the risk of IC bleed increased by 9%, 55%, and 59%, and the risk of GI bleed increased by 21%, 28%, and 39%, respectively. At age ≥75 years, prasugrel was associated with a greater risk of IC bleed than clopidogrel. At age ≥60 years, ticagrelor was associated with a greater risk of GI bleed than clopidogrel. Conclusions: More potent P2Y12-Is (prasugrel and ticagrelor) were associated with a disproportionately higher risk of IC bleed with increasing age compared with that of clopidogrel-prasugrel was much worse than clopidogrel at age ≥75 years. All three drugs were associated with only modest increase in the risk of GI bleed with every decade increase in age-ticagrelor was much worse than clopidogrel at ≥60 years of age. These results highlight the need for head-to-head clinical trials for the use of P2Y12-Is in patients with ESKD to determine age cutoffs where the risk of bleeding outweighs the benefits of thrombosis prevention.